- Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Kanzaki H, Hoshida Y
- KMID: 2563481
- Clin Mol Hepatol.
- 2025 Jan;31(1):e121-e122.
- doi: 10.3350/cmh.2024.0886
-
- CITED
-
- Close
- SHARE
-
- Close
- Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Kanzaki H, Hoshida Y
- KMID: 2563437
- Clin Mol Hepatol.
- 2025 Jan;31(1):308-310.
- doi: 10.3350/cmh.2024.0726
-
- CITED
-
- Close
- SHARE
-
- Close
- Switching to systemic therapy after locoregionaltreatment failure: Definition and best timing
-
Ogasawara , Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi , Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N
- KMID: 2500378
- Clin Mol Hepatol.
- 2020 Apr;26(2):155-162.
- doi: 10.3350/cmh.2019.0021n
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE... -
- CITED
-
- Close
- SHARE
-
- Close
- Postoperative Bleeding Risk after Gastric Endoscopic Submucosal Dissection in Patients Receiving a P2Y12 Receptor Antagonist
-
Hirai R, Kawano S, Inoo S, Kuraoka S, Okanoue S, Satomi T, Hamada K, Kono Y, Kanzaki H, Iwamuro M, Kawahara Y, Okada H
- KMID: 2542342
- Gut Liver.
- 2023 May;17(3):404-411.
- doi: 10.5009/gnl220196
Background/Aims: The safety of gastric endoscopic submucosal dissection (ESD) in users of a P2Y12 receptor antagonist (P2Y12RA) under current guidelines has not been verified. Methods: Patients treated by gastric ESD at... -
- CITED
-
- Close
- SHARE
-
- Close
- Does Helicobacter pylori Exacerbate Gastric Mucosal Injury in Users of Nonsteroidal Anti-Inflammatory Drugs? A Multicenter, Retrospective, Case-Control Study
-
Kono Y, Okada H, Takenaka R, Miura K, Kanzaki H, Hori K, Kita M, Tsuzuki T, Kawano S, Kawahara Y, Yamamoto K
- KMID: 2382346
- Gut Liver.
- 2016 Jan;10(1):69-75.
- doi: 10.5009/gnl14372
BACKGROUND/AIMS: The interaction between nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori remains controversial. We retrospectively investigated whether H. pylori infection exacerbates severe gastric mucosal injury among chronic NSAID users. METHODS: From... -
- CITED
-
- Close
- SHARE
-
- Close
